Skip to main content
Smart Investors Daily
NV

NYSE · NVST

Envista Holdings Corp

Healthcare · Medical - Equipment & Services

$22.91

Down-$0.36 (-1.55%)

Updated Nov 21, 2026, 1:04 PM

SID Score

4.7/10

Composite research score

Smart Money

58/100

Neutral

Market cap
3.64B
P/E ratio
244.84
Dividend yield
0.00%
52-week range
$18.79 – $30.42
Volume
2.31M
Avg. volume
2.08M

Price performance · NVST

NVST price history

1M range · 21 trading sessions · Daily adjusted prices

Prices through Nov 20, 2026

NVST closed at $22.91 after 21 trading sessions, down 2.92% for the selected period.

Last close
$22.91
Period change
-2.92%
Period low
$22.91
Period high
$27.19
Daily close
View OHLC price history
NVST OHLC price history, latest 40 sessions
DateOpenHighLowCloseVolume
Nov 20, 2026$23.21$23.76$22.77$22.912.31M
Nov 19, 2026$23.75$23.82$23.025$23.272.45M
Nov 18, 2026$23.49$24.09$23.43$23.751.92M
Nov 17, 2026$23.87$24.406$23.47$23.702.99M
Nov 16, 2026$24.44$24.97$23.89$24.032.33M
Nov 13, 2026$24.76$24.976$24.475$24.491.79M
Nov 12, 2026$25.18$25.495$24.64$24.662.27M
Nov 11, 2026$25.78$25.935$25.19$25.322.35M
Nov 10, 2026$25.75$26.10$25.29$25.842.19M
Nov 9, 2026$25.32$26.44$25.03$25.973.42M
Nov 6, 2026$24.63$25.2694$24.13$25.173.23M
Nov 5, 2026$26.625$27.18$24.62$24.965.49M
Nov 4, 2026$25.35$27.37$25.35$27.196.11M
Nov 3, 2026$24.50$25.405$24.37$24.775.53M
Nov 2, 2026$23.82$24.94$23.71$24.714.04M
Oct 30, 2026$24.72$24.90$23.40$23.513.73M
Oct 29, 2026$24.17$24.68$24.03$24.612.92M
Oct 28, 2026$23.51$23.95$23.51$23.943.19M
Oct 27, 2026$23.77$23.94$23.47$23.582.06M
Oct 26, 2026$23.60$23.93$23.43$23.663.15M
Oct 23, 2026$23.82$24.10$23.515$23.602.77M

Latest NVST news

The latest Smart Investors Daily articles mentioning NVST.

NVST research

Overview

Company profile and research snapshot.

Company profile

Envista Holdings Corp is a dental products company. It develops, manufactures, and markets portfolios of dental consumables, equipment, and services to dental professionals. The company's business consists of two segments; Specialty Products & Technologies and Equipment & Consumables. The company's Specialty Products & Technologies segment, which derives key revenue, develops, manufactures, and markets dental implant systems, including regenerative solutions, dental prosthetics, and associated treatment software and technologies, as well as orthodontic bracket systems, aligners, and lab products. Geographically, the company generates a majority of its revenue from North America, followed by Western Europe and other developed and emerging markets.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
—
Average target
$24.00
Implied upside
—
Analysts
—
NVST recent ratings
DateFirmRatingTarget
Nov 5, 2026Evercore ISI GroupOutperform—
Nov 5, 2026UBSNeutral—
Oct 15, 2026BairdNeutral—
Oct 14, 2026Leerink PartnersOutperform—
Oct 9, 2026Piper SandlerNeutral—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Nov 10, 2026

Envista Announces Pricing of $430 Million of Senior Notes

Envista Holdings Corporation (NYSE: NVST) ("Envista") today announced that it has priced an offering (the "Offering") of $430 million in aggregate principal amount of its 6.250% Senior Notes due 2033 (the "Notes") at the issue price of 99.482% of their principal amount.

Yahoo · Nov 8, 2026

Envista’s Q3 2026 earnings call: our top 5 analyst questions

Envista’s latest quarter reflected stable demand in core dental markets but was overshadowed by ongoing macroeconomic uncertainty, particularly in the U.S. and China. Management noted that insurance-covered categories like prevention and diagnostics remained resilient, while elective areas such as ortho and implants lagged historical growth. CEO Paul Keel attributed the company’s margin expansion to continued factory and general administrative productivity, despite China’s sales contraction due

Yahoo · Nov 6, 2026

Envista (NVST) Stock Could Trade Below Fair Value Following A 42% Fall

Envista Holdings has delivered a solid rebound over the past year, which puts a fresh spotlight on a tougher long term picture and raises a clear question for investors about whether today’s share price lines up with the cash flows the business is expected to produce. Over 5 years the stock is down 41.8%, which puts past capital losses front and center when you weigh what the current valuation implies for future cash generation. Recent earnings and revenue performance, along with...

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.